Izzy Wood (Drug Target Review)2023-07-05T12:03:58
Using a newly developed algorithm and a validation study, US researchers find that cancer hijacks a class of enzyme mutations to fuel tumorigenesis.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-09-24T06:30:00Z
Contributor Dr Dan Benjamin, Drug Target Review
2026-05-05T13:24:00
Sponsored by HUB Organoids
2023-12-11T10:49:07
Sponsored by Leica Microsystems
2026-08-03T06:00:00
Author Dr Xiaoxiao Wang, Yan Zhang and Junli Zhao
2026-05-26T09:05:00
Contributor Thomas Clozel M.D., Drug Target Review
2025-11-13T14:00:00
Sponsored by Cell Signaling Technology
2025-08-05T13:42:00
Sponsored by ICON plc., Drug Target Review
Site powered by Webvision Cloud